Milestone
4.2.a
Use cases
In progress
Develop use cases for broadly protective vaccines, including, for example, pan-H5 vaccines for pandemic response, to define how, where, and under what circumstances such vaccines would be used.
Progress Highlights
The WHO FVIVA (WHO 2026) defined nine use cases for existing and “improved” (categorized as minimally improved, significantly improved, and game changer) seasonal influenza vaccines, as a component of the estimate of the potential market for improved influenza vaccines. The FVIVA incorporates the primary use case defined in WHO’s updated PPC guidance, regarding the prevention of severe seasonal influenza illness through routine immunization of high-risk groups in LMICs.